ePT--the Electronic Newsletter of Pharmaceutical Technology, Oct 20, 2011 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

ePT--the Electronic Newsletter of Pharmaceutical Technology, Oct 20, 2011
News
FDA Publishes Guidance on Physical–Chemical Identifiers
By Erik Greb
Last week, FDA published a final guidance for pharmaceutical manufacturers that plan to incorporate physical–chemical identifiers in solid oral dosage forms as an anticounterfeiting strategy.
Roche to Acquire Anadys Pharmaceuticals
By Rich Whitworth
Roche signed a definitive agreement to acquire Anadys Pharmaceuticals. The two companies have entered into a definitive merger agreement for Roche to fully acquire Anadys at a price of $3.70 per share in an all-cash transaction.
Government Accountability Office Investigates Doctor Shopping
By Amy Ritter
At the request of the US Senate Subcommittee on Federal Financial Management, Government Information, Federal Services, and International Security, the Government Accountability Office conducted an investigation into doctor shopping in Medicare Part D.
SOCMA, PhRMA Welcome Passage of Free-Trade Pacts
By Patricia Van Arnum
The US Senate and House of Representatives passed last week three separate free-trade pacts with South Korea, Colombia, and Panama. The Society of Chemical Manufacturers and Affiliates and the Pharmaceutical Research and Manufacturers of America both issued statements expressing support for the legislation.
Acino Acquires Cephalon's Middle East and African Business
By Stephanie Sutton
Switzerland's Acino Pharma has agreed to buy Cephalon's combined Middle East and African business in a transaction worth approximately EUR 80 million ($110 million). Acino will pay 60 million Euro ($82.5 million) in cash and an additional EUR 20 million ($27.5 million) will come through shares.
Week of Oct. 17, 2011: Pfizer Signs Drug-Development Pact with GlycoMimetics; Lilly Announces Changes in Senior Management; and More
Pfizer Signs Drug-Development Pact with GlycoMimetics; Lilly Announces Changes in Senior Management; and More.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
41%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Click here